Brainstorm Cell Therapeutics (BCLI) : Traders are bullish on Brainstorm Cell Therapeutics (BCLI) as it has outperformed the S&P 500 by a wide margin of 20.88% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 15.53%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 17.26% in the last 1 week, and is up 26.16% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 19.38% and the 50-Day Moving Average is 25.53%.
Brainstorm Cell Therapeutics (NASDAQ:BCLI): The stock opened at $3.50 on Friday but the bulls could not build on the opening and the stock topped out at $3.87 for the day. The stock traded down to $2.86 during the day, due to lack of any buying support eventually closed down at $2.99 with a loss of -16.01% for the day. The stock had closed at $3.56 on the previous day. The total traded volume was 3,586,071 shares.
The company Insiders own 23.7% of Brainstorm Cell Therapeutics shares according to the proxy statements. Institutional Investors own 9.23% of Brainstorm Cell Therapeutics shares. In a related news, Shorr Robert G L, director of Brainstorm Cell Therapeutics Inc., unloaded 10,800 shares at an average price of $2.71 on December 16, 2015. The total amount of the transaction was worth $29,268, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrigs disease), Multiple Sclerosis and Parkinsons disease, among others. The Companys NurOwn technology is based on a differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells, MSC-NTF cells, capable of releasing several neurotrophic factors, including Glial-derived neurotrophic factor, Brain-derived neurotrophic factor, Vascular endothelial growth factor and Hepatocyte growth factor, which are critical for the growth, survival and differentiation of developing neurons. NurOwn is in clinical development for the treatment of ALS. It has completed two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center. It has been granted Fast Track designation and Orphan Status.